The Emirates Drug Establishment has approved Inpefa® (sotagliflozin), an innovative treatment for heart failure, making the UAE the second country in the world to authorise this therapy.
The move reinforces the nation’s leadership in adopting advanced pharmaceutical innovations and strengthening its healthcare system.
Inpefa is the first dual SGLT1 and SGLT2 inhibitor approved for heart failure treatment. It’s an oral medication that not only regulates blood sugar but also supports heart and kidney health.
The therapy aims to reduce deaths from cardiovascular disease, lower hospital admissions, and cut urgent medical visits for adults with heart failure, type 2 diabetes, chronic kidney disease, or other risk factors.
Heart failure is a serious condition that limits the heart’s ability to pump blood effectively, leading to complications and frequent hospitalisation.
Studies show Inpefa can significantly reduce these risks, with benefits starting early for patients who begin treatment during hospital stays.
Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, says the approval reflects the UAE’s commitment to timely access to safe, advanced treatments and its focus on global best practices in pharmaceutical regulation.
#EmiratesDrugEstablishment approves Inpefa, an oral medication helps regulate blood glucose levels while supporting heart and kidney health. reflecting the UAE’s leadership in adopting innovations & strengthening healthcare system.#DrugInnovation #DrugSecurity pic.twitter.com/QY5POmt0Vu
— Emirates Drug Establishment مؤسسة الإمارات للدواء (@EDE_UAE) January 12, 2026
Saqr Humanitarian Ship to support Gaza relief efforts
Mega EV charging hub opens on Abu Dhabi–Dubai highway
H.H. Sheikh Mansoor opens Intersec 2026
H.H. Sheikh Hamdan launches campaign to celebrate Emirati culture
